The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
Open accessAbstract
Mutant IDH1 coexpressed with inactivating TP53 and ATRX mutations in glioma enhances DNA repair, causing resistance to genotoxic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationCeccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189
Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,083
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Self-citationIDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Self-citationEndogenous DNA damage as a source of genomic instability in cancer
Tubbs, A., & Nussenzweig, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.002 · Cited by 1,452
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Self-citationRadiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027 · cited 1×
“IDH1R132H has been identified as an early event in glioma development, preceding TP53 and ATRX mutations (5, 6).”
Xu, Y., Ashley, T., Brainerd, E. E., Bronson, R. T., Meyn, M. S., & Baltimore, D. (1996) · Genes & Development · doi:10.1101/gad.10.19.2411 · Cited by 827
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
On testing the significance of sets of genes
Efron, B., & Tibshirani, R. (2007) · The Annals of Applied Statistics · doi:10.1214/07-aoas101 · Cited by 798
Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 555
annotatr: genomic regions in context
Cavalcante, R. G., & Sartor, M. A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx183 · Cited by 502
Self-citationDNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity
Henson, J. D., Cao, Y., Huschtscha, L. I., Chang, A. C., Au, A. Y. M., Pickett, H. A., & Reddel, R. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1587 · Cited by 498
Mutant IDH1 regulates the tumor-associated immune system in gliomas
Amankulor, N. M., Kim, Y., Arora, S., Kargl, J., Szulzewsky, F., Hanke, M., Margineantu, D. H., Rao, A., Bolouri, H., Delrow, J., et al. (2017) · Genes & Development · doi:10.1101/gad.294991.116 · Cited by 405
Karim, A. B. M. F., Afra, D., Cornu, P., Bleehan, N., Schraub, S., De Witte, O., Darcel, F., Stenning, S., Pierart, M., & Van Glabbeke, M. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02692-x · Cited by 389
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
Koschmann, C., Calinescu, A.-A., Nunez, F. J., Mackay, A., Fazal-Salom, J., Thomas, D., Mendez, F., Kamran, N., Dzaman, M., Mulpuri, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8228 · Cited by 290
Self-citationModeling Adult Gliomas Using RCAS/t-va Technology
Hambardzumyan, D., Amankulor, N. M., Helmy, K. Y., Becher, O. J., & Holland, E. C. (2009) · Translational Oncology · doi:10.1593/tlo.09100 · Cited by 280
Self-citationMaintenance of primary tumor phenotype and genotype in glioblastoma stem cells
Wakimoto, H., Mohapatra, G., Kanai, R., Curry, W. T., Yip, S., Nitta, M., Patel, A. P., Barnard, Z. R., Stemmer-Rachamimov, A. O., Louis, D. N., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor195 · Cited by 244
Inoue, S., Li, W. Y., Tseng, A., Beerman, I., Elia, A. J., Bendall, S. C., Lemonnier, F., Kron, K. J., Cescon, D. W., Hao, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.018 · Cited by 195
Use of Bru-Seq and BruChase-Seq for genome-wide assessment of the synthesis and stability of RNA
Paulsen, M. T., Veloso, A., Prasad, J., Bedi, K., Ljungman, E. A., Magnuson, B., Wilson, T. E., & Ljungman, M. (2014) · Methods · doi:10.1016/j.ymeth.2013.08.015 · Cited by 194
Self-citationWakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190
De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA
Wiesner, S. M., Decker, S. A., Larson, J. D., Ericson, K., Forster, C., Gallardo, J. L., Long, C., Demorest, Z. L., Zamora, E. A., Low, W. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1800 · Cited by 171
Li, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., PHILLIPS, H. S., Selfridge, J. M., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 169
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
Analysis of DNA Double-strand Break (DSB) Repair in Mammalian Cells
Seluanov, A., Mao, Z., & Gorbunova, V. A. (2010) · Journal of Visualized Experiments · doi:10.3791/2002 · Cited by 140
Self-citationWahl, M. T., Phillips, J. J., Molinaro, A. M., Lin, Y., Perry, A., Haas-Kogan, D. A., Costello, J., Dayal, M., Butowski, N. A., Clarke, J. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now176 · Cited by 131
Grana, T. M., Rusyn, E. V., Zhou, H., Sartor, C. I., & Cox, A. D. (2002) · PubMed · Cited by 130
Garrett, M. C., Sperry, J., Braas, D., Yan, W., Le, T. M., Mottahedeh, J., Ludwig, K., Eskin, A., Qin, Y., Levy, R., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0177-4 · Cited by 94
Serrano, L., Liang, L., Chang, Y., Deng, L., Maulion, C., Nguyen, S. C., & Tischfield, J. A. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0159 · Cited by 80
Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells
Godek, K. M., Venere, M., Wu, Q., Mills, K. D., Hickey, W. F., Rich, J. N., & Compton, D. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1154 · Cited by 74
Herting, C. J., Chen, Z., Pitter, K. L., Szulzewsky, F., Kaffes, I., Kaluzová, M., Park, J. C., Cimino, P. J., Brennan, C., Wang, B., et al. (2017) · Glia · doi:10.1002/glia.23203 · Cited by 67
Self-citationIDH mutation is associated with higher risk of malignant transformation in low-grade glioma
Leu, S., von Felten, S., Frank, S., Boulay, J., & Mariani, L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2048-y · Cited by 64
Historical perspective on the DNA damage response
Hanawalt, P. C. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.10.001 · Cited by 63
Keßler, J., Güttler, A., Wichmann, H., Rot, S., Kappler, M., Bache, M., & Vordermark, D. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.08.007 · Cited by 44
Broad-Enrich: functional interpretation of large sets of broad genomic regions
Cavalcante, R. G., Lee, C. K., Welch, R., Patil, S. B., Weymouth, T. E., Scott, L. J., & Sartor, M. A. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu444 · Cited by 20
Self-citation
Cited by
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0814-x · Cited by 657
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy
Gregory, J. V., Kadiyala, P., Doherty, R., Cadena, M., Habeel, S., Ruoslahti, E., Lowenstein, P. R., Castro, M. G., & Lahann, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19225-7 · Cited by 293
Self-citationEpigenetic encoding, heritability and plasticity of glioma transcriptional cell states
Chaligne, R., Gaiti, F., Silverbush, D., Schiffman, J. S., Weisman, H. R., Kluegel, L., Gritsch, S., Deochand, S. D., Gonzalez Castro, L. N., Richman, A. R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00927-7 · Cited by 258
TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma
Sun, R., Han, R., McCornack, C., Khan, S., Tabor, G. T., Chen, Y., Hou, J., Jiang, H., Schoch, K. M., Mao, D. D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3559 · Cited by 119
Metadata
- Authors
- Núñez, F. J., Mendez, F. M., Kadiyala, P., Alghamri, M. S., Savelieff, M. G., Garcia-Fabiani, M. B., Haase, S., Koschmann, C., Calinescu, A.-A., Kamran, N., Saxena, M., Patel, R., Carney, S., Guo, M. Z., Edwards, M., Ljungman, M., Qin, T., Sartor, M. A., Tagett, R., Venneti, S., Brosnan-Cashman, J., Meeker, A., Gorbunova, V., Zhao, L., Kremer, D. M., Zhang, L., Lyssiotis, C. A., Jones, L., Herting, C. J., Ross, J. L., Hambardzumyan, D., Hervey-Jumper, S., Figueroa, M. E., Lowenstein, P. R., & Castro, M. G.
- Venue
- Science Translational Medicine
- Published
- 2019-02-13
- Volume
- 11
- Issue
- 479
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2887976258
- Cited by
- 269
- References
- 51
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.